2024-01-04 12:09:02
Paris, Thursday January 4, 2024 — Public Health France has decided to expand its monitoring of the potential effects of endocrine disruptors.
Probable disruptors of the hormonal system, even reproductive health and the thyroid, possible risk factors for the development of hormone-dependent cancers and suspected in many pathologies: endocrine disruptors (EP) are accused of numerous ailments, with high levels evidence, however, varies greatly.
Currently, Public Health France has been carrying out specific surveillance of PE since 2015, focusing on reproductive health. However, to integrate new scientific knowledge, the French organization launched the PEPS’PE project in 2021, with the objective of prioritizing the health effects linked to PE and identifying health events to be integrated into its surveillance.
Advertisement
500 experts interviewed as part of the PEPS’PE project
As part of this project, it conducted a very broad consultation of experts, researchers and scientists in order to establish its new strategy. Five hundred personalities, French and international, were interviewed. “The objective was to obtain a classification of health effects into four priority categories, from highest to lowest, as a decision-making tool to identify health events to be integrated into the health surveillance strategy. public France in connection with endocrine disruptors», Details the health agency.
This survey made it possible to identify 59 health effects suspected of being linked to exposure to endocrine disruptors. Two criteria were retained: the weight of evidence and the epidemiological and societal interest in the health effect.
21 effects under priority surveillance by Public Health France
Among these effects, 21 were assessed as “priority” and to be monitored. Six of them affect reproductive health and were already the subject of specific vigilance, namely: cryptorchidism, hypospadias, early puberty, testicular cancer, alteration of sperm quality and endometriosis.
Other important consequences are also at the top of the list: metabolic effects (overweight and obesity, cardiovascular diseases, type 2 diabetes and metabolic syndrome) and neurodevelopmental disorders in children (behavioral disorders, intellectual deficit and attention deficit disorders). SPF also mentions cancers (breast cancer, prostate cancer, lymphomas and leukemias in children), and asthma.
Other effects, however, were considered “non-priority” or “low priority” and some might not be prioritized at all due to a lack of scientific experts on these themes and a lack of consensus. The French organization indicates that bone disorders, adrenal disorders and skin and eye disorders are among them.
Finally, Public Health France underlines the need to evolve its surveillance scope beyond reproductive health to integrate new pathologies. “Thanks to the first decision elements obtained through this study, Public Health France will analyze the feasibility of setting up monitoring of effects classified as priority», Indicates the agency in conclusion.
Raphael Lichten
© 2023 JIM SA. All rights reserved.
1704371208
#Endocrine #disruptors #Public #Health #France #expands #system